Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Matinas Biopharma Holdings Inc’s current trading price is -95.81% away from its 52-week high, while its distance from the 52-week low is 80.00%. The stock’s price range over this period has fluctuated between $0.50 and $21.50. The company, operating within the financial sector, had a trading volume of approximately 1.79 million for the day, which was noticeably higher than the average daily share volume of 0.17 million over the last 3 months.
Matinas Biopharma Holdings Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $21.50 on 03/22/24 and a low of $0.50 for the same time frame on 11/06/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Matinas Biopharma Holdings Inc (MTNB) has experienced a quarterly decline of -88.18% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.66M and boasts a workforce of 32 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.3620, with a change in price of -7.0950. Similarly, Matinas Biopharma Holdings Inc recorded 129,116 in trading volume during the last 100 days, posting a change of -88.74%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for MTNB stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.13.
MTNB Stock Stochastic Average
Today’s raw stochastic average for Matinas Biopharma Holdings Inc over the last 50 days is 10.03%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 10.67%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 5.78% and 3.14%, respectively.
MTNB Stock Price Performance Analysis
The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. The metric has seen a significant loss of -91.67% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -89.86%. Over the past 30 days, the price of MTNB has leaped by -71.70%. And in the last five days, it has surged by 58.62%.
